title: Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response.
abstract: Dendritic cells (DCs) transfected with total amplified tumor cell RNA have the potential to induce broad antitumor immune responses. However, analytical methods required for quantitatively assessing the integrity, fidelity, and functionality of the amplified RNA are lacking. We have developed a series of assays including gel electrophoresis, northern blot, capping efficiency, and microarray analysis to determine integrity and fidelity and a model system to assess functionality after transfection into human DCs. We employed these tools to demonstrate that modifications to our previously reported total cellular RNA amplification process including the use of the Fast Start High Fidelity (FSHF) PCR enzyme, T7 Powerswitch primer, post-transcriptional capping and incorporation of a type 1 cap result in amplification of longer transcripts, greater translational competence, and a higher fidelity representation of the starting total RNA population. To study the properties of amplified RNA after transfection into human DCs, we measured protein expression levels of defined antigens coamplified with the starting total RNA populations and measured antigen-specific T cell expansion in autologous DC-T cell co-cultured in vitro. We conclude from these analyses that the improved RNA amplification process results in superior protein expression levels and a greater capacity of the transfected DCs to induce multifunctional antigen-specific memory T cells.Molecular Therapy-Nucleic Acids (2013) 2, e91; doi:10.1038/mtna.2013.18; published online 7 May 2013.
authors: Argos Therapeutics, Durham, North Carolina, USA.
authors: Jacoba G
authors: JG
authors: Slagter-Jäger
authors: Alexa
authors: A
authors: Raney
authors: Whitney E
authors: WE
authors: Lewis
authors: Mark A
authors: MA
authors: Debenedette
authors: Charles A
authors: CA
authors: Nicolette
authors: Irina Y
authors: IY
authors: Tcherepanova
references: Mol Ther. 2012 May;20(5):948-53
references: 22334017
references: Cell. 1997 Jun 13;89(6):951-61
references: 9200613
references: Blood. 2001 Jul 1;98(1):49-56
references: 11418462
references: AIDS. 2012 Feb 20;26(4):F1-12
references: 22156965
references: Nucleic Acids Res. 1998 Jul 1;26(13):3208-14
references: 9628920
references: Nat Rev Immunol. 2008 Apr;8(4):247-58
references: 18323851
references: Nat Biotechnol. 2011 Feb;29(2):154-7
references: 21217696
references: Oncology. 2005;69(5):399-407
references: 16319511
references: J Transl Med. 2008 Apr 29;6:21
references: 18445282
references: Immunol Rev. 2004 Jun;199:251-63
references: 15233739
references: J Immunol. 2005 Mar 15;174(6):3798-807
references: 15749921
references: J Immunol. 2008 Oct 15;181(8):5296-305
references: 18832685
references: Nature. 2009 Jan 22;457(7228):426-33
references: 19158789
references: Curr Opin Mol Ther. 2007 Oct;9(5):423-31
references: 17932806
references: J Immunother. 2008 Feb-Mar;31(2):180-8
references: 18481387
references: Cancer Res. 2000 Feb 15;60(4):1028-34
references: 10706120
references: Biochim Biophys Acta. 2005 Jun 20;1724(1-2):127-36
references: 15866517
references: BMC Clin Pathol. 2009 Jun 09;9:5
references: 19505339
references: Nucleic Acids Res. 2005 Mar 30;33(6):e56
references: 15800207
references: J Surg Res. 2002 Jun 1;105(1):17-24
references: 12069496
references: Mol Ther. 2010 Dec;18(12):2112-20
references: 20628358
references: Med Oncol. 2003;20(4):335-48
references: 14716029
references: RNA. 1995 Nov;1(9):957-67
references: 8548660
references: Mol Ther. 2011 May;19(5):990-9
references: 21189474
references: Annu Rev Biochem. 1999;68:913-63
references: 10872469
references: Nucleic Acids Res. 2011 Nov;39(21):e142
references: 21890902
references: J Clin Invest. 2000 Nov;106(9):1065-9
references: 11067858
references: RNA. 2001 Oct;7(10):1486-95
references: 11680853
references: Clin Cancer Res. 2007 Aug 15;13(16):4740-9
references: 17699851
references: Chem Biol. 2012 Jan 27;19(1):60-71
references: 22284355
references: Methods Mol Biol. 2013;969:55-72
references: 23296927
references: J Immunother. 2011 Jan;34(1):45-57
references: 21150712
references: J Clin Invest. 2002 Feb;109(3):409-17
references: 11828001
references: Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39
references: 16469371
references: Clin Immunol. 2010 Feb;134(2):140-7
references: 19889582
references: J Biol Chem. 1980 Feb 10;255(3):903-8
references: 6243301
references: J Transl Med. 2006 Aug 15;4:35
references: 16911798
references: J Biol Chem. 2005 Dec 9;280(49):40707-13
references: 16215231
references: J Immunol. 2001 Mar 1;166(5):2953-60
references: 11207244
references: J Immunother. 2008 Oct;31(8):731-41
references: 18779746
references: BMC Mol Biol. 2008 Oct 17;9:90
references: 18928538
references: Gene Ther. 2003 Mar;10(5):367-74
references: 12601391
references: Int J Biol Sci. 2010 Oct 13;6(7):639-48
references: 20975822
references: Protein Eng. 1999 Dec;12(12):1035-40
references: 10611396
references: J Biomed Biotechnol. 2010;2010:623687
references: 20625504
references: BMC Mol Biol. 2006 Jan 31;7:3
references: 16448564